
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is a promising biopharmaceutical company with a strong focus on precision medicine for neurodegenerative diseases. The company's innovative approach using active immunotherapy has several advantages over traditional passive immunotherapy, including reduced cost and longer-lasting responses. Their pipeline looks promising, with multiple clinical programs targeting misfolded proteins associated with AD and PD, along with a versatile platform for developing both small molecule imaging agents and oral anti-aggregation agents. With upcoming data readouts for various programs, including the potential for significant plaque removal and improvements in motor and cognitive function in the PD program, AC Immune's potential for success is high.
Bears say
AC Immune is focusing on developing vaccines to potentially treat neurodegenerative diseases associated with protein misfolding. However, there are technical risks to these programs as the vaccines make assumptions about the structure of the toxic species and success may be dependent on biomarkers that are not fully established. Additionally, the company's AD program may be more biologically de-risked than their PD program due to the correlation between plaque clearance and cognitive benefit, while the readout for the AD trial is also better established compared to the PD trial.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares